Recursion Provides Business Updates and Reports Fourth
Multiple clinical programs from Recursion’s first generation platform are on track to read out Phase 2 data in H2 2024 and H1 2025 with additional second...
Stay updated with breaking news from Recursion Co. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Multiple clinical programs from Recursion’s first generation platform are on track to read out Phase 2 data in H2 2024 and H1 2025 with additional second...
Initiated five clinical trials in 2022, including three Phase 2 programs, and provided guidance on the timing of clinical data readoutsDelivered against...
/PRNewswire/ -- Recursion (NASDAQ: RXRX) today announced the release of its inaugural Environmental, Social and Governance (ESG) Report, highlighting the...
Announced a transformational collaboration with Roche and Genentech to build and navigate maps of biology in neuroscience and an indication in gastrointestinal...
/PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery,...